| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Stock Options (Right to Buy) | 100,000 | $152,000 | $1.52 | 07 Jun 2023 | Direct |
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Common Stock | 22,515 | $2,337 | $0.1038 | 09 Dec 2022 | Direct |
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Restricted Stock Units | 32,500 | 09 Dec 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| BLPH | Bellerophon Therapeutics, Inc. | 07 Jun 2023 | 1 | $0 | 4 | Chief Executive Officer, Principal Financial and Accounting Officer | 09 Jun 2023, 16:12 |
| BLPH | Bellerophon Therapeutics, Inc. | 10 Feb 2023 | 1 | $152,000 | 4 | CHIEF EXECUTIVE OFFICER | 14 Feb 2023, 15:46 |
| BLPH | Bellerophon Therapeutics, Inc. | 09 Dec 2022 | 3 | -$9,287 | 4 | PRINCIPAL EXECUTIVE OFFICER | 13 Dec 2022, 16:25 |
| BLPH | Bellerophon Therapeutics, Inc. | 26 Jan 2022 | 1 | $0 | 4 | CHIEF REGULATORY & SAFETY OFFR | 28 Jan 2022, 15:31 |